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Two studies (Shah et al., 2009; Mastrogiannaki et al., 2009) show that the hypoxia inducible factor HIF-2a is
a major player in regulating iron absorption by directly controlling the transcription of iron transporters in the
intestine in response to changes in mucosal iron or oxygen levels. The HIF-2amechanism has major effects
on iron metabolism which can override the well-known hepcidin-ferroportin regulatory axis.Prior to the discovery of hepcidin, the duodenal mucosa itself
was believed to be an important site for regulating the entry
of iron into the body, and it was thought by many in the field
that cells of the crypts were involved in sensing body iron
levels. This was called the ‘‘crypt cell sensing hypothesis’’
(initially proposed by Conrad and Crosby (1963) (for recent
review, see Roy and Enns, 2000), which stated that increased
body iron requirements led to early changes in the crypt enter-
ocyte iron content, then subsequently to changes in iron trans-
porter expression in mature enterocytes. Thus, there was
a delay between changes in body iron requirements and
changes in iron absorption, since it takes 1–2 days for a crypt
cell to mature and migrate to the villus tip. Tantalizing evidence
had supported this idea without providing a truly robust confir-
mation (Schumann et al., 1999; Trinder et al., 2002) as molec-
ular mechanisms for iron regulation of iron absorption gene
transcription had not yet been completely described. Posttran-
scriptional control of iron metabolism genes has, however,
been well studied (Muckenthaler et al., 2008). Iron regulatory
proteins (IRP1 and 2) bind to iron-responsive elements in
mRNA’s for key iron metabolism proteins when iron levels are
low and either block translation (e.g., in the case of the iron
storage protein ferritin) or increase mRNA stability (in the
case of proteins such as transferrin receptor 1 that are involved
in cellular iron uptake). The IRP/IRE translational/mRNA degra-
dation mechanism has been shown to operate on ferroportin
(Fpn, the iron efflux protein that transports iron from intestinal
cells [enterocytes] to blood) in the duodenum (Galy et al.,
2008). This control mechanism was thought to link systemic
regulation of iron absorption (see below) to local control by
changes in enterocyte iron level (Chen et al., 2003). The ubiq-
uitous IRP system, however, may be viewed as primarily
operating to control cellular levels of iron for housekeeping
purposes. The effect of IRP’s on ferroportin mRNA would
mean that low enterocyte iron levels would result in a block
in ferroportin mRNA translation. This is contradicted by the
observation that iron absorption is enhanced in iron deficiency.
A recent study by Zhang et al. (2009) has provided a mecha-
nism that can resolve this apparent contradiction between
the enterocyte’s own housekeeping iron needs and body iron
requirements. Zhang et al. showed that alternate splicing leads
to a minor fraction of ferroportin mRNA that lacks the IRE
(Fpn1B), thereby meaning that ferroportin translation is only84 Cell Metabolism 10, August 6, 2009 ª2009 Elsevier Inc.partially controlled by enterocyte iron levels. This finding helps
explain why IRP2 knockout (KO) has remarkably little effect on
iron absorption rates (Galy et al., 2005). The mRNA for the
highly iron-regulated apical ferric reductase (Dcytb) has no
IRE, and therefore its regulation has never been adequately
explained by the IRP system. A more rapid local intestinal
regulation was deduced from the observation that a bolus of
oral iron taken before iron absorption measurements resulted
in downregulation of absorption of subsequent doses of iron
(referred to as the mucosal block) (Hahn et al., 1943). This was
thought to be due to ‘‘local’’ control of iron transporter expres-
sion by iron. Molecular investigation of the latter has shown
downregulation of the major brush border membrane iron
transporter DMT1 and Dcytb at the protein level (Yeh et al.,
2000; Frazer et al., 2003) and mRNA level (Frazer et al., 2003).
In recent years, focus has shifted away from the intestine to the
liver as the major site for control of iron metabolism, as this is
where hepcidin is produced. The discovery of hepcidin as a
liver-expressed peptide that regulated iron absorption (reviewed
by Ganz, 2008) was a major breakthrough and prompted Frazer,
Anderson, and coworkers to carefully analyze the time depen-
dence of iron absorption responses and changes in gene
expression in both the intestine and liver in response to physio-
logical challenges to iron metabolism (Frazer et al., 2002; 2003).
Their data suggested much that had been attributed to local
sensing and regulation of absorption by the intestine, could be
explained by liver sensing changes in body iron requirements
with hepcidin acting as a hormone to negatively regulate iron
absorption. The demonstration that hepcidin binds to the iron
transporter ferroportin resulting in its degradation (Nemeth
et al., 2004) seemed to offer the key that finally unlocked the
‘‘local’’ iron absorption regulation riddle. Hepcidin binding to fer-
roportin would lead to blocking of iron efflux to the plasma, which
in turn might result in increases in enterocyte iron that could
downregulate the intestinal iron uptake proteinsDMT1andDcytb
(Frazer et al., 2003)—but the mechanism for this downregulation
remained obscure. Mouse KO studies strongly support the
suggestion that hepcidin is the most potent regulator of iron
absorption (Lesbordes-Brion et al., 2006); however, some indi-
rect evidence (Schumann et al., 1999; Raja et al., 2005) left
open the possibility that other regulatory mechanisms operate.
Hypoxia inducible factor (HIF) was initially discovered as
the major oxygen regulated transcription factor that controls
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thereby links tissue oxygen supply to red cell production. HIF
levels are regulated by a protein degradation pathway mediated
by the E3 ubiquitin ligase von Hippel-Lindau tumor suppressor
(VHL) (Maxwell et al., 1999), and an oxygen-sensing mechanism
is provided by the action of prolyl hydroxylases (PHD) enzymes
that modify the a subunit of HIF, thus labeling it for degradation
by VHL (Epstein et al., 2001) (Figure 1). Other proteins are essen-
tial for the HIF/PHD mechanism, including VHL, which is essen-
tial for the hydroxylation reaction and Arnt (HIF-1b), which forms
the HIF transcription factor complex. The HIF system shows
tissue specificity through variable expression of the several HIF
alpha subunit isoforms (HIF-1a, HIF-2a, HIF-3a) and PHD iso-
forms (PHD1, PHD2, PHD3). A growing list of proteins involved
in iron metabolism have been identified as HIF-responsive
targets, including Transferrin receptor 1, Ceruloplasmin, Heme
Oxygenase 1, and hepcidin (Peyssonnaux et al., 2008). Prolyl
hydroxylases require not only oxygen, but also iron and ascor-
bate in order to hydroxylate HIF; thus, PHDs can potentially act
as iron sensors (Berra et al., 2006) and HIF could operate as an
iron-sensitive transcription factor.
Two recent papers have now turned iron regulation on its head
again by providing compelling data that the duodenum is both an
important sensor and regulator of iron absorption through
regulation of iron transport proteins by the transcription factor
HIF-2a, with PHDs emerging as potential iron sensors in the
mucosa. DMT1 and particularly Dcytb are among the genes
most highly upregulated by both iron deficiency and hypoxia in
the duodenum. While DMT1 contains a 30IRE, Dcytb does not
have a recognizable IRE, and hence its strong regulation by
iron and hypoxia have always been unexplained. In the first
study, Shah et al. (2009) showed that liver-specific KO of either
HIF1a alone or both HIF-1a and HIF-2a had virtually no effect
on response to iron deficiency, indicating this response does
not require liver HIFs. The authors then focused on the role of
HIFs in the intestine. First they showed that HIF-2a but not
HIF-1amRNA was induced in the duodenum by iron deficiency.
They then found an intestinal-specific VHL KO (which blocks HIF
degradation) produced a large induction of HIF-2a but not
HIF-1a expression and made the interesting finding that both
Dcytb and DMT1 were among the genes most highly activated
in duodenum of these mice, suggesting that both Dcytb and
DMT1 were transcriptionally regulated by HIF-2a. Furthermore,
both proteins and, in the case of Dcytb, functional ferric reduc-
tase activity were increased in the intestine of VHL KO mice.
Moreover, VHL KO mice became iron overloaded despite an
intact hepcidin response. Using an intestine specific double
VHL/HIF-1a KO mouse model, they still found robust upregula-
tion of Dcytb and DMT1, thus implying that the effects were
due to HIF-2a rather than HIF-1a. In contrast to VHL KO mice,
in double VHL/Arnt KO mice (Arnt is required for the formation
of functional HIF-1a and HIF-2a transcription complexes) the
effects on iron metabolism seen in VHL KO mice (increased
DMT1 and Dcytb mRNA and protein; increased functional ferric
reductase activity and iron loading) were all reversed. The
authors then went on to characterize a number of hypoxia
response elements (HREs) within the promoter regions of the
Dcytb and DMT1 genes, demonstrating that HIF-2a but not
HIF-1a activated transcription.Interestingly, the authors found that the intestinal Arnt KOmice
in fact became anemic and had lower serum iron when fed an
iron-deficient diet due to the lack of a transcriptional response
of Dcytb and DMT1 genes (lowered hepcidin levels were not
able to compensate for this effect), thus providing strong if indi-
rect physiological evidence for the role of HIF-2a.
Whereas Shah et al. used VHL KO and double VHL/HIF-1a
KO to indirectly show effects of HIF-2a, in a second paper,
Mastrogiannaki et al. (2009) directly and selectively deleted
HIF-1a and HIF-2a in the intestine. Whereas intestinal deletion
of HIF-1a had no effect on iron metabolism, intestinal HIF-2a
KO had a similar phenotype to intestinal Arnt KO mice reported
Figure 1. Overview of Transcriptional Control of Intestinal Iron
Transport Genes by HIF-2a
HIF-2a but not HIF-1a is a major iron-inducible transcription factor controlling
transcription of iron transporters within enterocytes. Increases in intracellular
iron (Fe), oxygen (O2), or ascorbate (Asc) levels increase prolyl hydroxylase
(PHD) activity, leading to degradation of HIF-2a via von Hippel-Lindau
(VHL) -mediated ubiquitilation (Ub), reduced DMT1, Dcytb, and FPN transcrip-
tion and reduced dietary iron absorption. Conversely, decreases in intracel-
lular iron (e.g., in dietary iron deficiency), oxygen, or ascorbate lead to reduced
enterocyte PHD activity, increased HIF-2a levels, increased transcription of
iron transporters, and increased iron uptake. HIF-2a-induced changes in
iron transport can override the effects of the hepcidin-ferroportin regulatory
pathway.Cell Metabolism 10, August 6, 2009 ª2009 Elsevier Inc. 85
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Dcytb, Fpn, and hepcidin-reduced iron stores, serum iron,
and hemoglobin. The only difference was that Shah et al.
only saw effects on iron metabolism of Arnt KO on an iron-defi-
cient diet, whereas Mastrogiannaki et al. observed effects of
HIF-2a deletion even on a regular diet. One point of conflict
between the Shah et al. and Mastrogiannaki et al. studies was
that the former implied that loss of the intestinal HIF mechanism
led to loss of iron sensing in the intestine. Mastrogiannaki et al.
found that intestinal HIF-2a KO mice retained a significant
responsiveness of Dcytb and DMT1 mRNA levels to dietary
iron deficiency, suggesting an additional iron sensing mecha-
nism is present.
HIFs are of course more widely associated with oxygen,
rather than iron sensing. It has long been known that hypoxia
induces a very early increase in iron absorption (Hathorn,
1971) at 6–8 hr after onset of hypoxia. This increase precedes
alterations in serum or plasma iron, erythropoiesis (Hathorn,
1971; Raja et al., 1988), or hepcidin (G.O. Latunde-Dada and
R.J. Simpson, unpublished data) and is due to increases in
the mucosal uptake of iron (Raja et al., 1988). HIFs acting as
local sensors of enterocyte oxygen provide an explanation
for this early response. The additional requirement of PHDs for
ascorbate adds an extra degree of complexity to the regulation
of HIFs. Iron, oxygen, and ascorbate are closely linked, not only
metabolically, but also, the three can react together chemically,
and duodenal levels of ascorbate tend to change in the opposite
direction to changes in iron, increasing in iron deficiency (Atana-
sova et al., 2005). Further study is required to figure out how
these factors coordinately regulate iron absorption via regula-
tion of PHDs.
It also appears that the HIF-2a regulation of DMT1 explains
some puzzling aspects of DMT1 regulation by iron that were
not explained by the DMT1 IRE. Galy et al. (2008) showed in an
intestine-specific IRP1 plus IRP2 KO that DMT1 non-IRE mRNA
was upregulated and DMT1-IRE was only mildly decreased.
This, taken with more drastic effects of the IRP KO on other
IRE-regulated proteins, had implied some transcriptional upre-
gulation of DMT1 gene. The enterocytes of the IRP double intes-
tinal KOmice were likely to be severely functionally iron deficient
due to upregulation of Fpn and ferritin protein, and the HIFmech-
anism now provides amolecular mechanism for a compensatory
increase in DMT1 gene transcription.
Both the Shah et al. and Mastrogiannaki et al. studies showed
that modulation of HIF-2a in the intestine altered serum iron and
iron stores, with HIF-2a intestinal KO and Arnt intestinal KO
causing anemia and VHL intestinal KO causing iron overload.
Their data suggested that the hepcidin mechanism and liver
iron sensing were functioning correctly but was unable to coun-
teract the altered expression of iron transporters in the intestine.
Interestingly, there are suggestions that HIF-2a may exert
more control on the apical iron uptake pathway (Dcytb and
DMT1) than the basolateral iron transport (FPN and Hephaestin)
(Mastrogiannaki et al. show a significant effect on Fpn; how-
ever, the effect is not significant in the Shah et al. studies). If
confirmed, such a mechanism could explain earlier data, which
showed that iron ingestion rapidly changes duodenal DMT1
and Dcytb mRNA levels but leaves FPN and Hp unchanged
(Frazer et al., 2003).86 Cell Metabolism 10, August 6, 2009 ª2009 Elsevier Inc.The papers together are an important advance not only
because they shine a light on how Dcytb, DMT1, and ferroportin
are transcriptionally regulated by iron and hypoxia, but also
because they provide a major molecular mechanism to explain
how local changes in enterocyte iron (as in the mucosal block
phenomenon) or oxygen alter duodenal transporter expression
and dietary iron absorption. They may therefore suggest new
gene candidates for inherited defects in iron absorption and
show that alterations in HIFs at the intestinal level can override
systemic regulation via hepcidin. This may therefore provide
alternative therapeutic strategies for interventions in control of
iron absorption in iron-overload conditions. Such alternatives
could focus on local control of iron absorption at the intestinal
level.
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